Restructuring Push and Performance Turnaround Mingde Biotech Faces Delisting Risk Warning and Claims

Ask AI · Why does the reversal of performance guidance trigger a wave of investor claims?

Recently, Mindray Bio (002932) released an announcement regarding progress on a major asset restructuring. The company plans to purchase 100% of the equity in Wuhan Bekaer Rescue Supplies Co., Ltd. (hereinafter referred to as “Bekaer”), held by Blue Sail Medical, using cash; it is expected to constitute a major asset restructuring. Currently, the audit, appraisal, and due diligence are being advanced normally, and no formal agreement has yet been signed; there are major uncertainties regarding the transaction.

Mindray Bio first disclosed this major asset restructuring plan on December 31, 2025. Mindray Bio stated that this integration will strongly promote the company’s integrated business for diagnosis and treatment of critical illnesses—from medical institutions to industrial scenarios and home scenarios—thereby building a coordinated ecosystem of “diagnosis—protection—treatment,” and further improving the company’s asset quality and profitability, as well as consolidating and enhancing its market position and overall competitiveness in the field of critical illnesses. If the acquisition is completed smoothly, Mindray Bio will gain control of Bekaer and include it within the scope of consolidated financial statements.

Mindray Bio may also be subject to a delisting risk warning by the Shenzhen Stock Exchange after the company discloses its 2025 annual performance. The company expects that, after audit, the total profit, net profit, and net profit excluding non-recurring gains and losses for 2025 will be negative, and that the operating revenue after exclusion will be less than 300 million yuan.

On the evening of March 22, Mindray Bio disclosed the “Amendment Announcement on 2025 Annual Performance Forecast.” The announcement shows that the company made a substantial downward revision to the performance forecast it released on January 31. Previously, the company expected 2025 net profit to be a gain of RMB 12 million to RMB 18 million; after revision, it became a loss of RMB 15 million to RMB 25 million. In addition, the non-recurring profit and loss adjusted net profit was originally expected to be a loss of RMB 78 million to RMB 98 million, and has expanded to a loss of RMB 100 million to RMB 140 million.

Mindray Bio’s “reversal” of its performance forecast and its failure to promptly warn of risks may trigger a large number of investor claims. Zhao Jingguo, a lawyer from Shanghai Xinben Law Firm, believes that investors who bought and held Mindray Bio’s stock during the period from January 31, 2026 to March 22, 2026 may claim compensation against the company, regardless of whether they still hold the stock after March 23, 2026. Eligible investors may register and sign up through the public account “大众证券报” (feature code: 88). The final claim eligibility will be determined by the court.